Development of Nasal Lipid Nanocarriers Containing Curcumin for Brain Targeting
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Curcumin (CUR) has properties that can be useful for the treatment of Alzheimer’s disease. Such properties are the inhibition of amyloid-β-protein (Aβ) aggregation, Aβ-induced inflammation, and activities of β-secretase and acetylcholinesterase. However, previous studies have revealed that CUR exhibited low bioavailability and difficulties in reaching the brain. Objective: To overcome such drawbacks, this study aims at developing nasal lipid nanocarriers loaded with CUR to effectively target the brain. Methods: The lipid nanocarriers (NE) were prepared using the hot solvent diffusion associated with the phase inversion temperature methods. Physico-chemical and morphological characterizations and in vitro drug release of the nanocarriers were carried out. The CUR permeation/retention was analyzed in Franz-type diffusion cell using porcine nasal mucosa. Confocal laser scan and histopathological studies were also performed. Results: The results showed that the NE sizes ranged between 18 nm and 44 nm with negative zeta potential. The CUR content ranged from 0.24 to 1.50 mg/mL with an encapsulation efficiency of 99%. The profiles of CUR release indicated a biphasic kinetics. CUR-NE permeation across the porcine nasal mucosa was higher when compared to free CUR. These results have also been validated through an analysis on a confocal microscopy. In addition, no toxicity on the nasal mucosa has been observed in a histopathological analysis. Conclusion: These results suggest that it is possible to develop NEs with a high content of CUR and small particle size. Such an encapsulation increases the potential of CUR permeation across the porcine nasal mucosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907 · cited 1×
“Inthecaseofintranasaladministration,thePNM wasusedtotestthepassageofdrugsthroughthe nasalmucosa,aimingtotargetthecompoundsto theCNS[49].”
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Neuroprotective effects of curcumin
Cole, G. M., Teter, B., & Frautschy, S. A. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_8 · Cited by 516
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450
Intranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435
Ahmed, T., & Gilani, A.-H. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.09.010 · Cited by 301
Sood, S., Jain, K., & Gowthamarajan, K. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2013.09.030 · Cited by 289
Ross, T. M., Martinez, P. M., Renner, J. C., Thorne, R. G., Hanson, L. R., & Frey, W. H. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.02.011 · Cited by 242 · cited 1×
“More recently, the trigeminal pathway has been recognized as a complementary delivery pathway to the CNS, especially to reach the caudal brain regions and spinal cord [7, 8].”
Martins, R. N., Harper, C. G., Stokes, G. B., & Masters, C. L. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb00615.x · Cited by 234
Nasr, M. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1092619 · Cited by 208
Cited by
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Microglial Cells: The Main HIV-1 Reservoir in the Brain
Wallet, C., De Rovere, M., Van Assche, J., Daouad, F., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Van Lint, C., Rohr, O., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00362 · Cited by 368
Formulations of Curcumin Nanoparticles for Brain Diseases
Del Prado-Audelo, M. L., Caballero-Florán, I. H., Meza-Toledo, J. A., Mendoza-Muñoz, N., González-Torres, M., Florán, B., Cortés, H., & Leyva-Gómez, G. (2019) · Biomolecules · doi:10.3390/biom9020056 · Cited by 191
“7 EE ≥ 99 Permeation in Franz cells (ex vivo model) [118]”
BackgroundLong, Y., Yang, Q., Xiang, Y., Zhang, Y., Wan, J., Liu, S., Li, N., & Peng, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104795 · Cited by 151
Drug targeting strategies into the brain for treating neurological diseases
Barnabas, W. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.015 · Cited by 70
Metadata
- Authors
- Vaz, G. R., Hädrich, G., Bidone, J., Rodrigues, J. L., Falkembach, M. C., Putaux, J.-L., Hort, M. A., Monserrat, J. M., Varela Junior, A. S., Teixeira, H. F., Muccillo-Baisch, A. L., Horn, A. P., & Dora, C. L.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-07-17
- Volume
- 59
- Issue
- 3
- Pages
- 961-974
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2736373785
- Cited by
- 50
- References
- 10
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.